Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patie...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Stem Cells Dev
Hlavní autoři: Sengupta, Vikram, Sengupta, Sascha, Lazo, Angel, Woods, Peter, Nolan, Anna, Bremer, Nicholas
Médium: Artigo
Jazyk:Inglês
Vydáno: Mary Ann Liebert, Inc., publishers 2020
Témata:
Clinical Trial
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7310206/
https://ncbi.nlm.nih.gov/pubmed/32380908
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/scd.2020.0080
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky